For ImmunoGen, A Lot Depends On Herceptin-Based Conjugate T-DM1
This article was originally published in The Pink Sheet Daily
Executive Summary
Eight compounds currently in the clinic rely on ImmunoGen's technology for creating antibody-cytotoxin linked cancer drugs, with another two to four expected to reach that stage in 2010